OnCo
technologiesTechnologyEstablished

High-risk pancreatic surveillance (CAPS / PRECEDE)

Yearly MRI or endoscopic ultrasound for people with inherited risk, which catches pancreatic cancers while they are still operable.

The Cancer of the Pancreas Screening (CAPS) consortium and the PRECEDE consortium (>50 centres) follow carriers of BRCA2, PALB2, ATM, CDKN2A, STK11, Lynch genes, and familial pancreatic cancer kindreds with annual MRI/MRCP or EUS. In CAPS5 (2022), 77% of screen-detected cancers were stage I versus ~15% in the general population, with 5-year survival ~73%. Blood tests (CA19-9 glycan variants, MCED) and AI on prior CTs aim to extend surveillance to new-onset diabetes and other higher-risk groups.

Schematic · not to scale
Annual MRI / EUS · Cyst or early lesion

How it works

Annual cross-sectional imaging of the pancreas in a population with 5-10x baseline risk; resection of high-grade precursor lesions and early cancers.

Strengths
  • Stage shift to resectable disease in carriers
  • Defines the population for blood-test validation
Limitations
  • Only ~10% of pancreatic cancers arise in identifiable high-risk groups
  • Cyst overtreatment risk
  • Cost and adherence

Latest papers

top
Literature trend0 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"High-risk pancreatic surveillance" OR ABSTRACT:"High-risk pancreatic surveillance" OR TITLE:"CAPS / PRECEDE" OR ABSTRACT:"CAPS / PRECEDE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about High-risk pancreatic surveillance (CAPS / PRECEDE), not a curated reading list.

Connected

12top

Pages like this

not linked directly; found by shared links